Dr. Qing Zou 邹青
Chief Physician
Department of General Surgery, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of kidney, prostate, bladder, penile, and testicular tumors, including minimally invasive surgery and comprehensive therapies.
Dr. Zou graduated from Nanjing Medical University in 1987. Dr. Zou worked at Nanjing First Hospital (1987–2003) and has been at Jiangsu Cancer Hospital since 2003, currently serving as Director of the Urology Department. A master’s supervisor at Xuzhou Medical University, Dr. Zou participates in multi-center clinical trials and has published numerous articles, including over 10 SCI papers.
Professional roles
- Member, Urology Professional Committee, Jiangsu Medical Association
- Vice Chair, Urological and Male Genital Tumor Professional Committee, Jiangsu Anti-Cancer Association
- Member, Urology and Male Reproductive System Professional Committee, China Anti-Cancer Association
- National Member, Particle Nuclear Medicine Professional Committee
Name order: in Chinese the family name comes first (Zou Qing). Papers usually list the name as Qing Zou or Zou Q.
Selected publications
18 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur Urol, 2023 (senior author): Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010. PubMed 36604272
- Ann Transl Med, 2019 (senior author): Clinical characteristics and genetic testing of an atypical familial von Hippel-Lindauzon renal cell carcinoma. PubMed 31930078
- Transl Androl Urol, 2019 (senior author): A new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy. PubMed 31555557
- Ann Transl Med, 2018 (senior author): Efficacy characteristics of different therapeutic modalities for locally advanced prostate cancer: a Bayesian network meta-analysis of randomized controlled trials. PubMed 30370285
- Int J Biol Markers, 2018 (senior author): Genetic variants in macrophage colony-stimulating factor are associated with risk of renal cell carcinoma in a Chinese population. PubMed 29734839
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion